Reticulocyte & Red Cell Patents: Who Leads, Where Gaps Are 2026
- 33.2% concentration at the top. The five leading assignees combined account for 631 of the 1,903 records in scope, with a long tail of single- and few-filing entrants below them.
- Filings have pulled back from a 2017 peak. Annual filings ran from 121 in 2017 down to 66 in 2021 and 29 in 2024, a -56% move over that three-year span, though the most recent years are still filling in as publication catches up.
- Therapeutic and diagnostic claims dominate the IPC mix. A61K medicinal preparations touch 57.2% of records and A61P therapeutic activity 36.5%, while G06F digital data processing sits at just 3.9% — a narrow lane compared with the chemistry-heavy core.
Filing growth compares 2021 (66 records) with 2024 (29) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 1,903 records in scope (CR5), not by the ranked leaders only.
What this patent landscape covers
This landscape draws on 1,903 patent records filed against reticulocyte count, erythrocyte parameter and red cell indices technology, cross-referenced against hemoglobin content, fluorescent staining, anemia classification, reference interval work, lipemia interference and clinical utility claims. The scope spans both the diagnostic instrumentation side of red cell analysis — flow cytometry, fluorescent staining protocols, reference interval calibration — and the therapeutic side, where erythropoietin fusion proteins and related biologics dominate citation counts. Publication lags filing by roughly 18 months, so any read of the most recent one or two years understates real filing activity.
The mix of A61K, A61P and C07K classes alongside G01N material analysis and testing points to a field where drug-development claims around erythropoiesis-stimulating agents sit close to, and sometimes overlap, instrument and assay claims for counting and characterising red cells. Anyone filing here needs to check both sides of that line.
Filing trend and technology composition
Two views of the same 1,903-record dataset: how filing activity has moved year on year, and which IPC subclasses carry the claim weight.
Filing trend: peak, pullback, and the reporting lag
Filings peaked in 2017 at 121 and have since declined, reaching 66 in 2021 and 29 in 2024 — a -56% move over that span. Treat 2025 and 2026 figures as provisional; they will rise as more publications clear the roughly 18-month lag between filing and disclosure.
Where the claims sit across IPC subclasses
A61K medicinal preparations (57.2% of records) and A61P therapeutic activity (36.5%) lead the composition, with C07K peptides and proteins (31.5%) and G01N material analysis and testing (30.3%) close behind. Genetic engineering, enzymatic and data-processing classes each sit under 10%, marking them as smaller, less-crowded corners of the same field.
Shares are the percentage of the 1,903 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Reticulocyte and Red Cell Parameters with Eureka
This page is one run against one query. Ask Eureka your own question about reticulocyte and red cell parameters and every answer comes back with the patent numbers behind it.
Try EurekaA representative record and the most-cited prior art
Single-cell modeling of clinical data to determine red blood cell regulation (US20220293210A1)
The filing describes a method that compares two complete blood counts taken from the same subject at different times, each recording the volume and hemoglobin content of individual red blood cells, then calculates parameters representing red blood cell population dynamics from the change between samples. The stated aim is deriving a pathophysiological signal from longitudinal single-cell CBC data rather than population averages alone.Assignee and filing date are rendered separately above.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2005063808A1 | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS | 515 |
| 2 | US20090299645A1 | Genetic analysis | 391 |
| 3 | US20050202538A1 | Fc-erythropoietin fusion protein with improved pharmacokinetics | 380 |
| 4 | US20050192211A1 | Fc-erythropoietin fusion protein with improved pharmacokinetics | 355 |
| 5 | US6866823B2 | Apparatus for analyzing biologic fluids | 344 |
| 6 | US5939326A | Method and apparatus for performing automated analysis | 320 |
| 7 | US5891734A | Method for performing automated analysis | 317 |
| 8 | US5631165A | Method for performing automated hematology and cytometry analysis | 291 |
| 9 | WO2003104270A2 | Dudulin 2 genes, expression products, non-human animal model: uses in human hematological disease | 284 |
| 10 | US6723290B1 | Container for holding biologic fluid for analysis | 282 |
Citation counts reflect influence within the searched corpus and favour older records; they are not a measure of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data signals for R&D and IP strategy
Four read-outs from the filing pattern, concentration figures and citation data that matter for deciding where to file next.
Filing is concentrated but not locked up
The top 5 assignees combined hold 33.2% of the 1,903 records in scope, and the top 10 hold 45.8%. That leaves more than half the field spread across a long tail of entrants filing a handful of records each — room to build a position without displacing an incumbent.
Volume has pulled back from its 2017 peak
Annual filings fell from 66 in 2021 to 29 in 2024, continuing a decline from the 2017 peak of 121. Because publication lags filing by about 18 months, the 2025-2026 figures are not yet reliable evidence of a further slowdown.
Medicinal preparation claims dominate the class mix
A61K appears on 57.2% of the 1,903 records and A61P on 36.5%, confirming that erythropoiesis-related therapeutics carry more claim density than the instrumentation side. G01N material analysis, at 30.3%, is the largest purely diagnostic class.
Citation weight sits with early Fc-fusion erythropoietin filings
The most-cited records in this dataset are Fc-erythropoietin fusion protein filings from the mid-2000s, one drawing 515 citations. Their age and citation count reflect foundational status in erythropoiesis-stimulating biologics, not current filing activity.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to reticulocyte and red cell parameters, with the prior art for and against each one.
Who holds the strongest positions
The ranked leaders span both biologics developers working on erythropoiesis-stimulating agents and diagnostic instrument makers focused on red cell counting and characterisation — two groups whose claims occasionally intersect.
A single assignee holds more than double the second-place count
The leading assignee's 339 records sit well above fifth place at 52 and tenth place at 44, showing a steep drop-off rather than a gradual one. That gap suggests a dominant filer built its position early and has kept extending it across related claims.
Recent-year activity has cooled even among established filers
Several assignees that built substantial portfolios show zero filings in the latest tracked year, and one shows a -67% year-on-year drop. This is consistent with the broader 2021-2024 pullback rather than a company-specific retreat.
Co-assignee filing is limited but concentrated
Only 10 co-assignee pairs appear in this dataset, and the strongest pair co-files 27 records together. That points to occasional deep partnerships — likely licensing or joint-development arrangements around specific biologics — rather than broad industry-wide co-filing.
| Assignee | Recent year | YoY |
|---|---|---|
| Sysmex Corporation | 1 | -67% |
| Acceleron Pharma Inc. | 0 | — |
| Ambrx, Inc. | 0 | — |
| FibroGen, Inc. | 0 | — |
| Bayer Corporation | 0 | — |
| IDEXX Laboratories, Inc. | 0 | — |
| Amgen Inc. | 0 | — |
| Novartis AG | 0 | — |
Where to take this analysis
The figures here mark the shape of the field; deciding where to file, license or design around requires drilling into specific claim sets.
Check freedom to operate against the leading assignee's claims
With one assignee holding 339 records against a fifth-place figure of 52, any new filing in the core A61K/C07K space should be checked against that portfolio specifically before drafting.
Run a claim comparison in EurekaMap the under-claimed branches before drafting
Sub-areas like single-cell longitudinal CBC modelling and lipemia interference correction show thinner density than the core cluster — worth a targeted search before assuming the space is open.
Explore white space in EurekaTrack momentum, not just headline counts
Several top filers show zero activity in the latest tracked year. Understanding whether that reflects a strategic shift or the publication lag matters before reading too much into current rankings.
Monitor assignee activity in EurekaCommon questions on reticulocyte and red cell parameter patents
The dataset's assignee ranking shows a steep concentration at the top: the leading assignee holds 339 of the 1,903 records in scope, well ahead of the fifth-ranked assignee at 52 and tenth-ranked at 44. Together the top five assignees hold 33.2% of all records, and the top ten hold 45.8%. Below that top tier, filings spread across a long tail of assignees with far fewer records each, spanning both erythropoiesis-stimulating biologics developers and diagnostic instrument makers.
Filing peaked in 2017 at 121 records and has declined since, falling to 66 in 2021 and 29 in 2024 — a -56% change over that three-year span. However, publication typically lags actual filing by around 18 months, so the 2025 and 2026 figures in this dataset are still incomplete and should not be read as confirming a continued decline. The safest complete-year comparison currently available is the 2021-to-2024 window.
The IPC composition shows A61K (medicinal preparations) touching 57.2% of the 1,903 records and A61P (therapeutic activity) touching 36.5%, indicating a strong weighting toward erythropoiesis-related drug claims. C07K (peptides and proteins) and G01N (material analysis and testing) each cover roughly 30% of records, capturing biologic composition and diagnostic assay work respectively. Smaller shares in C12N, C12Q, C12P and G06F mark genetic engineering, enzymatic and data-processing sub-areas as comparatively less claimed.
US20220293210A1 describes a method for comparing two complete blood counts from the same subject taken at different times, using per-cell volume and hemoglobin content data to calculate red blood cell population dynamics parameters. It is narrow to the specific approach of deriving a pathophysiological signal from longitudinal single-cell CBC comparisons rather than covering red cell counting or hemoglobin measurement generally. A new filing focused on single-timepoint population averages, a different data pairing, or a different derived parameter would likely sit outside its claim scope, though a formal freedom-to-operate check against the full claim set is still advisable.
Sub-areas including single-cell longitudinal CBC modelling, lipemia interference correction algorithms, fluorescent reticulocyte staining reagents, and enzymatic red cell parameter assays under C12P show thinner claim density than the dominant A61K/A61P/C07K cluster. G06F-classed data-processing approaches to red cell parameter analysis also sit at just 3.9% of records, suggesting algorithmic and software-driven approaches to interpreting red cell data remain comparatively open. Any of these branches warrants a targeted prior-art search before assuming it is crowded, since low density here reflects less filing activity rather than confirmed freedom to operate.
Research Reticulocyte and Red Cell Parameters in depth with Eureka
Go past this page: query the whole reticulocyte and red cell parameters corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.